Ipsen Acquisition Trifecta Raises North American Stakes
French drug maker takes control of Tercica, Vernalis’ U.S. subsidiary and Octagen’s investigational hemophilia drug OB-1.
French drug maker takes control of Tercica, Vernalis’ U.S. subsidiary and Octagen’s investigational hemophilia drug OB-1.